Our brands:
Where tech meets bio.
WTMB Group publishes BioPharmaTrend, the Where Tech Meets Bio newsletter and The Biotech Edge. Since 2016 we have tracked the companies, deals and science reshaping pharma R&D. Vendors use us to reach that audience. Investors and strategy teams use us to understand it.
Who reads us
A concentrated audience of pharma R&D leaders, biotech founders, business development teams and investors.
15% R&D and discovery • 14% business development and strategy • 7% investors • 17% founders and executives
Four channels, one editorial team
Each channel reaches the same audience in a different way. Sponsors can book one or combine them.
BioPharmaTrend
The publicationIn-depth analysis of AI in drug discovery, company landscapes, interviews and news, with a ten-year archive.
20,000+ monthly readers • 9M+ yearly Google impressions
Where Tech Meets Bio
Email newsletterThe week in techbio: what happened, who raised, and what it means.
12,200+ subscribers • 32% open rate, 3.3% CTR
The Biotech Edge
LinkedIn newsletterShort, curated briefings on AI drug discovery and competitive moves, delivered inside LinkedIn.
26,000+ subscribers • 8,000+ views per issue
Fast takes on deals, launches and research from our founders and company page.
51,000+ followers, 3 channels • 7,000+ impressions per post
15% R&D and discovery • 14% business development and strategy • 7% investors • 17% founders and executives
Two ways we bring value
Reach industry decision makers
Run standalone campaigns or secure a year-round presence across all our media channels: BiopharmaTrend, Where Tech Meets Bio (Newsletter), The Biotech Edge (LinkedIn newsletter) and LinkedIn feed.
Request packages and prices →Understand the landscape
Get access to premium deep dives, case studies, news and topical reports on cutting edge technologies in the biopharmaceutical R&D, including AI drug discovery, lab automation, data generation, and manufacturing. PhD-level insights grounded in ten years of tracking the field.
BiopharmaTrend Pro →